BioStem Technologies

How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond

BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference

Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care

BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference

Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care

2022 Year in Review: BioStem Technologies Looks Back At A Year of Growth And Expansion

BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing

2022 Year in Review: BioStem Technologies Looks Back At A Year of Growth And Expansion

BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing

How The Personal Experience Of This Biotech Company's Leadership Became The Cornerstone Of Its Growth Story

Could BioStem's Perinatal Tissue-Based Products Be The Chronic Wound-Healing Solution Everyone Is Waiting For?

BioStem Technologies Recent News

Could Perinatal Allografts Be Charting A New Course In Wound Healing?

An allograft is tissue that is transplanted from one person to another. The prefix “allo” comes from a Greek word meaning “other.” An allograft is different from an autograft, which uses the individual's own tissue and is, therefore, genetically identical.

BioStem Technologies (OTCMKTS: BSEM) Coverage Initiated at Zacks Investment Research

The below report was authored by Brad Sorensen, CFA, Zacks Small Cap Research. You can find the original report here.

BioStem Technologies, Inc. Second Quarter Financial Results Call, August 22, 2022

C O R P O R A T E P A R T I C I P A N T S Nicolas Johnson, Russo Partners Jason Matuszewski, Chief Executive Officer Michael Fortunato, Controller C O N F E R E N C E C A L L P A R T I C I P A N T S

BioStem Technologies Reports 133% Year-Over-Year Revenue Growth As It Expands Distribution of Patented Allograft Tech

BioStem Technologies Inc. (OTCMKTS: BSEM) is a regenerative medicine company that develops and manufactures tissue allografts for use in surgery and wound care. In August, the company reported growth exceeding even its own expectations as net revenue increased to $2.2 million for the second quarter.

BioStem Technologies' Local MicroEnvironment Activation Possible Key To Reversing And Repairing Diseases-Caused Tissue Damage

Jason Matuszewski, CEO of BioStem Technologies Inc. (OTCMKTS: BSEM), was a guest speaker at Benzinga’s All Access on June 17th, 2022.